Search
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalIt is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome
Categories: Somatostatin Receptor AgonistsProducts: Mytolac 60 mg Injektionslösung in einer Fertigspritze, Mytolac 90 mg Injektionslösung in einer FertigspritzeSodium ascorbate
go.drugbank.com/drugs/DB14482ApprovedInvestigationalNutraceuticalMixtures: Se-Tan DHA, Se-Tan DHACategories: Compounds used in a research, industrial, or household settingDupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigational[A180478] As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in … It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsProducts: Dupixent 300 mg Solution for Injection in Pre-filled Syringe, Dupixent 200mg Solution for Injection in Pre-Filled SyringeEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigational[L5593] Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications … Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use.
Categories: NMDA Receptor Antagonists, Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsProducts: Eskelan 25 mg/ml-Injektions-/Infusionslösung in Ampullen, Eskelan 25 mg/ml-Injektionslösung in DurchstechflaschenOmalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigational[A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005. … [L50482] It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria, and asthma.[A263507]
Products: XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/1.0ML, XOLAIR SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.5MLSex hormone-binding globulin
go.drugbank.com/bio_entities/BE0000685CarrierTargetHumansSpecific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration … Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid.
Synonyms: Testosterone-estradiol-binding globulinParnaparin
go.drugbank.com/drugs/DB09260ApprovedParnaparin is an heparin of low molecular weight with antithrombotic effects.
Products: FLUXUM 0.3 ML 3200 IU 2 HAZIR SIRINGA, FLUXUM 0.3 ML 3200 IU 6 HAZIR SIRINGAVigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. … [A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Products: Vigabatrin for oral solution USP, 500 mgAmifostine
go.drugbank.com/drugs/DB01143ApprovedInvestigationalIt causes splenic vasodilation and may block autonomic ganglia.
Categories: Compounds used in a research, industrial, or household settingProducts: Ethyol - Pws IV 500mg/vial, ETHYOL 500 MG IV INFUZYON ICIN LIYOFIZE TOZ ICEREN FLAKON, 1 ADETAmiloride
go.drugbank.com/drugs/DB00594ApprovedInvestigationalThis inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. … Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
Categories: Decreased Renal K+ ExcretionProducts: Amiloride Hydrochloride Tablets, USP